Signal to Noise versus Titer: Is it time to adopt a new para...
After a busy spring and summer season of bioanalytical conferences, we are gearing up for a full sch...
Blog
New FDA Hepatic Impairment Guidance: What It Means for Your...
Sabina Paglialunga, PhD1; Natacha Benrimoh, MSc2; Angela Choi, PhD2; Aernout van Haarst, PhD1 Â 1. S...
Blog
When to Run a UGT-Mediated DDI Trial—and Why It Matters Clin...
Sabina Paglialunga, PhD & Aernout van Haarst, PhD, Senior Directors, Scientific Affairs, Celerio...
Blog
Cocktail DDI Studies: Myths vs. Facts
Sabina Paglialunga, PhD & Aernout van Haarst, PhD, Senior Directors, Scientific Affairs, Celerio...
Blog
The Resurgence of Antibody Drug Conjugates: How ADCs are tak...
Michelle Miller, PhD, Global Senior Scientific Director, Bioanalytical Services What is an ADC? Anti...
Blog
PBMCs or Whole Blood? Strategic Applications in Phase I Stud...
Your browser does not support the audio element. ⬇ Download MP3 Studying peripheral blood mononuclea...
Blog
The Rising Tide of Weight Reduction Therapies
Sabina Paglialunga, PhD Senior Director, Scientific Affairs Weight reduction drugs are making a big...
Blog
Rethinking Drug Development: The Role of Model-Informed Appr...
By Johannes Stanta, PhD, Global Scientific Director, Celerion Inc. As drug development continues to...
Blog
Smarter, Faster, Safer: Celerion Unveils Major Upgrade to La...
At Celerion, we believe that innovation in the lab shouldn’t come at the cost of simplicity or secur...